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Skp2 is well known as the F-box protein of the
SCFSkp2!Roc1 complex targeting p27 for ubiquitylation. Skp2
also forms complexes with cyclin A, which is particularly
abundant in cancer cells due to frequent Skp2 overexpres-
sion, but the mechanism and significance of this interaction
remain unknown. Here, we report that Skp2-cyclin A inter-
action is mediated by novel interaction sequences on both
Skp2 and cyclin A, distinguishing it from the well known
RXL-hydrophobic patch interaction between cyclins and
cyclin-binding proteins. Furthermore, a short peptide
derived from the mapped cyclin A binding sequences of Skp2
can block Skp2-cyclin A interaction but not p27-cyclin A
interaction, whereas a previously identified RXL peptide can
block p27-cyclin A interaction but not Skp2-cyclin A interac-
tion. Functionally, Skp2-cyclin A interaction is separable
from Skp2 ability to mediate p27 ubiquitylation. Rather,
Skp2-cyclin A interaction serves to directly protect cyclin
A-Cdk2 from inhibition by p27 through competitive binding.
Finally, we show that disruption of cyclin A binding with
point mutations in the cyclin A binding domain of Skp2 com-
promises the ability of overexpressed Skp2 to counter cell
cycle arrest by a p53/p21-mediated cell cycle checkpoint
without affecting its ability to cause degradation of cellular
p27 and p21. These findings reveal a new functional mecha-
nism of Skp2 and a new regulatory mechanism of cyclin A.
Skp2 is one of the founding members of the F-box protein
family that serves as the ubiquitylation substrate recruiting sub-
unit of the SCFSkp2!Roc1 complex (1). The best-established
substrate of Skp2 is the cyclin-dependent kinase inhibitor
(CKI)5 p27 (2–4), although Skp2 can also promote ubiquityla-
tion and degradation of other proteins including the p27 family
members p21 (5) and p57 (6). Because p27 is a negative regula-
tor of cell proliferation, the p27 ubiquitylation activity of Skp2
suggested that it is a proliferation-stimulating protein. Indeed,
Skp2 exhibits proliferation-stimulating activity in various
experimental assays and is found overexpressed in various
human cancers (7).
Anotherproperty of Skp2 is its interactionwith cyclinA. In fact,
Skp2 was first identified and cloned as a cyclin A-associated pro-
tein in transformed cells (8, 9), and Skp2 associated with both
cyclin A and Skp1 in stoichiometric amounts (9). If protein-pro-
tein interactions and the efficiencies of interactions are indications
of protein functions, these early findings should suggest that Skp2-
cyclin A interaction is an important aspect of Skp2 function.
Because overexpression of Skp2 is a frequent event in cancer cells
andcyclinAplays important roles incellproliferationandsurvival,
Skp2 may affect cyclin A function through this interaction as a
tumorigenic mechanism. Surprisingly, however, very little has
been learned about the Skp2-cyclin A interaction more than 10
years after its identification.WhetherSkp2belongs to the familyof
RXL-containing cyclinA-bindingproteins remains uncertain, and
the functional significance of Skp2-cyclin A interaction is contro-
versial (see below). Currently, the role of Skp2 as a proliferation-
stimulating protein has been exclusively attributed to p27 ubiqui-
tylation and degradation.
In this study we determined that Skp2-cyclin A interaction
represents a novel type of interaction between cyclin A and its
binding proteins. Our investigation of the significance of the
Skp2-cyclin A interaction reveals a new functional mechanism
of Skp2 and a new regulatory mechanism of cyclin A.
EXPERIMENTAL PROCEDURES
Plasmids, Antibodies, and Peptides—Skp2, Skp2 N terminus
(Skp2N), and p27 cDNAswere cloned into pGEX-2T. GST-p21
and GST-E2F1 are gifts from Anindya Dutta and Bill Kaelin,
respectively. GST-Skp2N-AA45 andGST-Skp2N-AAA53were
generated using the QuikChange kit from Stratagene. GST
moiety was cleaved off GST fusion proteins (GST-p27, GST-
Skp2N, andGST-Skp2N-AA45) by thrombin for certain exper-
iments. Myc-tagged cyclin A and mutant derivatives were
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generated by PCR. Various cDNAs were cloned under cyto-
megalovirus (CMV) promoter in lenti-CMV-GFP replacing
GFP (10). Other plasmids were described previously (11).
Antibodies to Myc (9E10), Cdk2 (M-2 and D-12), p53
(DO-1), p21 (C-19), cyclin A (H432 and C-19), cyclin E
(C-19), cyclin D1 (72–13G), Cdk4 (H-303), and Cul1 (H-213)
were from Santa Cruz. Anti-FLAG (F7425 and F3165) were
from Sigma. Anti-p27 was from was Pharmingen. Anti-Skp2
(51-1900 and 32-3300) was from Zymed Laboratories Inc.
Peptides RXL (SACRNLFG), 4060 (KTSELLSGMGVSALE-
KEE), and 4060AAAA (KTSEAASGMGVAAAEKEE) were
from GenScript.
Cell Culture, Transfection, Lentivirus Production, and Infec-
tion—Cell lines U2OS, HeLa, and 293T were maintained in
standard conditions. Transfection was performed with stand-
ard calcium phosphate protocol. To generate lentivirus stocks,
293T cells were transfected with various lentivirus vectors and
packaging vectors (pMDLg/pRRE, pRSV-REV, and pMD2-
VSVG) (10). Cell culture media at 48 h post-transfection were
either used directly or after concentration for infection of
U2OS cells at!90% efficiency.
Drug Treatment and Various Routine Assays—Actinomycin
D (Sigma) treatment was for 20–22 h at 180 nM. Etoposide
(Sigma) treatment was for 24 h at 10!M. To arrest HeLa cells in
mitotic phase, cells were treated with 100 ng/ml nocodazole
(Sigma) for 16–17 h. Western blotting, immunoprecipitation,
indirect immunofluorescence, and flow cytometry analysis to
determine cell cycle profiles were all performed with standard
protocols and as described previously (11).
GST Pull-down, p27 Ubiquitylation Assay, and Cyclin A
Kinase Assay—GST fusion proteins were purified on GSH
beads (Amersham Biosciences) that were then incubated with
transfected cell extracts for 1 h in 4 °C with rocking. The beads
were washed 3 times with lysis buffer (25mMHepes pH7.6, 100
mMKCl, 0.1 mM EDTA, 10mMMgCl2, 0.1%Nonidet P-40, 10%
glycerol, 1mMdithiothreitol) before analysis by SDS-PAGE and
Western blotting.
In vitro p27 ubiquitylation assay in Fig. 2B was performed as
described (11). Briefly, 293T cells were transfected with cytomeg-
alovirus expressionvectors forFLAG-Skp2 (wild typeormutants),
Myc-Roc1, Cul-1, and Skp-1, and the SCFSkp2-Roc1 complex was
immuno-purified with anti-FLAG. The immuno-complexes were
washed 3 times in 1" ubiquitylation assay buffer, and the ubiqui-
tylation reaction was performed by adding the following to the
beads in 1" ubiquitylation buffer (20 mM HEPES pH 7.2, 10 mM
MgCl2, 1 mM dithiothreitol): 250 ng of phosphorylated purified
p27, 1" energy regeneration system (ERS), 1 !g each E1 and
E2(Cdc34) (Boston Biochem), 10 !g of ubiquitin (Sigma), 1 !M
ubiquitin-aldehyde, 0.2mMMG132, 10 ng of purified Cks1, and 1
!M okadaic acid. Reaction mixtures were incubated at 30 °C for
2 h.After incubation, p27was immunoprecipitated from the reac-
tion with polyclonal anti-p27 antibody, resolved by SDS-PAGE,
and Western-blotted with a monoclonal anti-p27 antibody. In
vitro p27 ubiquitylation assay in Fig. 2B was performed as
described (12). Briefly, Roc1/HA-Cul1/His-Skp1/Skp2 (or Roc1/
HA-Cul1/His-Skp1/Skp2#N; HA is hemagglutinin) and His-cy-
clinA-Cdk2 complexeswere expressed in 5B insect cells andpuri-
fied by nickel-agarose chromatography (2). 2 !l of in vitro
translated 35S-labeled p27 were incubated at 30 °C for different
times in 10 !l of ubiquitinylation mix containing 40 mM Tris. pH
7.6, 5mMMgCl2, 1mMdithiothreitol, 10%glycerol, 1!Mubiquitin
aldehyde, 1 mg/ml methyl ubiquitin, 10 mM creatine phosphate,
0.1mg/ml creatine kinase, 0.5mMATP, 1!Mokadaic acid,$5 ng
of purified recombinant SCFSkp2 complex (or SCFSkp2#N), and 10
ng of purifiedCks1 and 250nMcyclinA-Cdk2 complex. Reactions
were stopped with Laemmli sample buffer, and their products
were run on protein gels under denaturing conditions. Polyubiq-
uitinylated p27 forms were identified by autoradiography.
Cyclin A-Cdk2 kinase assays were performed as described
previously (11). Both immuno-purified Myc-cyclin A-Cdk2 on
beads andGST-purified and -elutedGST-cyclinA-Cdk2 (bacu-
lovirus vectors for GST-cyclin A and Cdk2 were provided by
Brian Dynlacht) were used. The amounts of purified proteins
were determined by comparing them with known amounts of
standard proteins in Coomassie Blue-stained gels. Phosphoryl-
ation of GST-Rb-C was quantified with the ImageQuant soft-
ware. The Ki of various proteins was determined by non-linear
least squares analysis. To determine the amounts of various
proteins in synchronized HeLa cells, extracts representing
7.5 " 104 HeLa cells were resolved with known amounts of
purified proteins and compared in the same Western blots.
Actual amounts of proteins in 7.5 " 104 HeLa cells were then
determined (for example, the amounts of p27, Skp2, and cyclin
A in 7.5" 104 HeLa cells were determined to be about 0.1, 0.2,
and 0.1 pmol, respectively, at 14 h post-replating and about
0.01, 0.1, and 1.0 pmol, respectively, at 19 h post-replating).
Variousmolar ratioswere then calculated and shown in Fig. 7G.
RESULTS
Identification of a Novel Cyclin A BindingMotif in the Skp2N
Terminus—Mapping of cyclin A binding sequences on Skp2
has been attempted previously with discrepant results (13, 14)
(also see “Discussion”). Guided by the Skp2 crystal structure
(15), we first divided the full-length Skp2 protein at residue 150
(the NF and LRR fragments shown in Fig. 1C) without disrupt-
ing "-helices or #-sheets. In cotransfection assays, Skp2NF
bound cyclin A, whereas Skp2LRR did not (Fig. 1A). We then
determined that the N-terminal 100 residues fused with GFP
(Skp2N-GFP) were sufficient for cyclin A binding, indicating
that the F-box is not required (lanes 7 and 8).Wewent on to use
smaller deletions to map the amino acid residues necessary for
binding cyclinA to between residues 40 and 60 in the context of
full C-terminal sequences (Fig. 1, B and C).
A commonly used physical relationship between cyclins and
non-Cdk proteins is mediated between the RXL motif in the
interacting proteins (16, 17) and the hydrophobic patch (HP)
on cyclins (the RXL-HP interaction) (18, 19). Interestingly,
sequences between 40 and 60 of Skp2 do not contain a recog-
nizable RXL motif (Fig. 1D). This sequence, however, is nearly
completely conserved from human Skp2 to mouse and chicken
Skp2 orthologs. When the alignment is extended to fly Skp2,
four conserved residues can be identified. Mutation of these
four conserved residues to alanine (the Skp2AAAA mutant)
abolished the ability of the full-length Skp2 to bind cyclin A
(Fig. 1E). These results suggest that Skp2 uses a novel, non-RXL
cyclin A binding domain to interact with cyclin A.
Direct Protection of Cyclin A by Skp2
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Skp2-Cyclin A Interaction Is Separable from Skp2 Ability to
Mediate p27 Ubiquitylation—With the ability to disrupt Skp2-
cyclin A interaction with point mutations in the Skp2 N termi-
nus, we determined the role of this interaction in other known
biochemical properties of Skp2 by
comparing Skp2 and Skp2AAAA.
Because the cyclin A binding
domain is located N-terminal to
the F-box and an N-terminally
truncated Skp2 (Skp2#N) could
form complexes with Skp1-Cul1-
Roc1 (15, 20), we predicted that
Skp2AAAA should retain the ability
to form the SCFSkp2!Roc1 complex.
We tested this prediction by co-ex-
pressing the four components of
SCFSkp2!Roc1 complex into 293T
cells and immunoprecipitating Skp2
(or Skp2AAAA) via a FLAG tag on
Skp2. The results show that
Skp2AAAA was indeed capable of
forming the SCFSkp2AAAA!Roc1
complex (Fig. 2A).
We next determined whether the
SCFSkp2AAAA!Roc1 complex was
active as an ubiquitin ligase for p27.
Immunopurified SCFSkp2!Roc1 and
SCFSkp2AAAA!Roc1 complexes sup-
plemented with E1 and E2 were
incubated with purified p27 that
had been first phosphorylated by
cyclin E-Cdk2 or cyclin A-Cdk2.
Results shown in Fig. 2B demon-
strate that Skp2AAAA retained the
ability to ubiquitylate p27. No p27
ubiquitylation was observed when
p27 was not first phosphorylated by
cyclin E-Cdk2 or cyclin A-Cdk2
(data not shown). To confirm that
the binding to cyclin A is not neces-
sary for p27 ubiquitylation with
another Skp2 mutant, wild-type
Skp2 and Skp2#N were expressed
in insect cells using a baculovirus
system together with Skp1, Cul1,
and Roc1 and then purified by
nickel-agarose chromatography.
Skp2#N was able to induce p27
ubiquitylation similarly to wild-type
Skp2 (Fig. 2C). Similar results were
obtained when Skp2#N and wild-
type Skp2 were produced using a
rabbit reticulocyte system6 or with
bacterial-purified Skp2#N.7
Ser-76 in the Skp2 N terminus
can be phosphorylated by cyclin
A-Cdk2 (14). We determined
whether Skp2-cyclin A interaction
serves a substrate recruitment function and, therefore, is
6 A. C. Carrano and M. Pagano, unpublished results.
7 A. Hershko, personal communication.
FIGURE 1. Identification of Skp2 sequences required for binding cyclinA.A and B, 293T cells were transfected
with various expression vectors as indicated. Immunoprecipitation (IP)-Western blot assays were performed with
extractsof transfectedcells.Wt,wild type;LRR, leucine-rich repeat.C, a schematicdrawingofSkp2domainstructure,
variousmutants, and their ability to bind cyclin A, as determined in A and B. Numbering is basedonNCBI accession
numberU33761.NF,N terminusandF-box.D, alignmentofhumanSkp2sequence fromaminoacid residues40–60
withcorrespondingsequencesofSkp2orthologs indifferentspecies. Identical residuesareboxedandweremutated
to alanine in Skp2AAAA. E, immunoprecipitation-Western assay with transfected 293T cell extracts, as in A and B.
Direct Protection of Cyclin A by Skp2
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required for this phosphorylation. Results in Fig. 2C show that
disruption of interaction between cyclin A and the Skp2N by
point mutations (see also Fig. 3C) did not affect the phospho-
rylation of Ser-76 by cyclin A-Cdk2, suggesting that phospho-
rylation of Ser-76 does not require a stable association of Skp2
with cyclin A. Skp2 is a nuclear protein (13). We determined
whether Skp2-cyclin A interaction is required for its nuclear
localization. As shown in Fig. 2D, both Skp2 and Skp2AAAA
are localized in the nucleus when expressed in U2OS cells.
Based on these results, we conclude that Skp2-cyclin A interac-
tion is separable from these known properties of Skp2.
Skp2 Binds Cyclin A as Efficiently as p27—Wenext examined
the effects of Skp2-cyclinA interaction on cyclinA-Cdk2. p27 is
the best-understood RXL protein that binds cyclin A-Cdk2 as a
kinase inhibitor. As an approach to understanding the effects of
Skp2 on cyclin A-Cdk2, we undertook to compare Skp2-cyclin
A-Cdk2 interaction with p27-cyclin A-Cdk2 interaction.
We first compared the relative binding efficiencies of Skp2-
cyclin A-Cdk2 and p27-cyclin A-Cdk2. We used FLAG-tagged
Skp2 and p27 so that the amounts of these two proteins can be
compared with anti-FLAG antibody on Western blots. When
expressed at similar levels in transfected 293T cells (Fig. 3A,
total gels), similar amounts of FLAG-p27 and FLAG-Skp2 were
co-immunoprecipitated with the cotransfected cyclin A (Fig.
3A,myc IP gels). We next used GST pull-down assays to com-
pare the relative binding efficiencies in vitro. We first showed
that the Skp2 N terminus (Skp2N)
can bind cyclinA as efficiently as the
full-length Skp2 by titrating down
the input amounts of cyclin A-Cdk2
(Fig. 3B, lanes 1–6).When the bind-
ing efficiencies of Skp2N and p27
were compared in the titration
experiments, relative binding effi-
ciencies were again found to be sim-
ilar (Fig. 3B, lanes 7–15). In Fig. 3C
we demonstrate that point muta-
tions of the conserved residues in
the cyclin A binding sequence (40–
60) abolished cyclin A binding of
Skp2N. In this experiment we found
that mutations of two conserved
residues (eitherAA45 orAAA53) can
efficiently abolish cyclin A binding.
Finally, purified Skp2N (but not
Skp2NAA45) and purified p27 are
able to bind purified cyclin A-Cdk2
(Fig. 3D), indicating that Skp2-cy-
clin A interaction is also direct as
the p27-cyclin A-Cdk2 interaction.
Skp2 and p27 Bind to Different
Sequences on Cyclin A—Results in
Fig. 1 demonstrated that Skp2 uses a
novel non-RXL motif to interact
with cyclin A. We next investigated
whether the Skp2-cyclin A-Cdk2
interaction and the p27-cyclin
A-Cdk2 interaction also differ on
the side of cyclin A-Cdk2. An important feature for p27-cyclin
A-Cdk2 interaction is that, in addition to the RXL-HP interac-
tion, p27 also has extended interaction with the N-terminal
lobe of Cdk2, providing a structural basis for its inhibitory
effects on cyclin A-Cdk2 kinase (18). To compare this aspect of
p27 with Skp2, we expressed cyclin A and Cdk2 separately in
293T cells (levels of endogenous cyclin A or Cdk2 are not
expected to be sufficiently high to form significant amount of
complexes with transfected Cdk2 or cyclin A, respectively) and
determined the binding behavior of GST-p27 and GST-Skp2N
in these transfected extracts. As shown in Fig. 4A, GST-p27
binds cyclin A-Cdk2 complex as well as cyclin A or Cdk2 in
singly transfected extracts. In the same conditions, GST-Skp2N
binds cyclin A-Cdk2 and cyclin A alone but does not bind Cdk2
alone. The amount of Cdk2 is also less in GST-Skp2N-cyclin
A-Cdk2 pull-down than inGST-p27-cyclin A-Cdk2 pull-down,
which is consistent with p27, but not Skp2N, being also able to
bind free Cdk2.
We then attempted to localize Skp2 interaction sequences in
cyclin A in comparison with p27. Cyclin A contains two con-
served cyclin-box sequences that form two cyclin folds in the
cyclinA-Cdk2 crystal structure (21), which does not include the
N-terminal 172-amino acid residues (Fig. 4B). The HP that
mediates the interactionwith theRXLmotif of p27 is composed
of residues 210MRAILVDW in the "1 helix of the N-terminal
cyclin fold (18). Based on this information, we designed the
FIGURE 2. Skp2-cyclin A interaction is separable from other known activities of Skp2. A, immunoprecipi-
tation-Western assay with transfected 293T cell extracts as in (Fig. 1, A and B) except expression vectors for
SCFSkp2!Roc1 subunits were used. Skp2 was omitted in transfection for lane 3. Cells in lane 4 were mock-
transfected. Wt, wild type. B, in vitro p27 ubiquitylation assay using the immuno-purified complexes as shown
in A. Purified p27 was first phosphorylated by either purified cyclin E-Cdk2 or cyclin A-Cdk2 as indicated. C, in
vitro ubiquitin ligation assay of 35S-labeled in vitro translated p27 was conducted in the presence of purified
recombinant Cdk2-cyclin A complex and purified recombinant SCFSkp2 (lanes 2 and 3) or SCFSkp2#N (lanes 4 and
5). Similar results were obtained with purified recombinant Cdk2-cyclin E complex (not shown). Samples were
incubated at 30 °C for the indicated times. D, various purified GST fusion proteins, as indicated, were incubated
in kinase reactions with purified cyclin A-Cdk2. Coomassie Blue stain and autoradiograph of the same gel are
shown. E, U2OS cells were infected with lentiviruses expressing GFP, FLAG-tagged Skp2, or FLAG-tagged
Skp2AAAA. Expression andcellular localizationof Skp2was revealedby indirect immunofluorescence staining.
DAPI, 4%,6-diamidino-2-phenylindole.
Direct Protection of Cyclin A by Skp2
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following cyclin A mutants to map and compare Skp2 and p27
binding sequences as shown in Fig. 4, B and C. Cyclin A
sequences 1–303 (consisting of the N-terminal cyclin fold and
the N terminus) bound to p27 and Skp2N to a similar extent as
the full-length cyclin A (please compare the relative amounts in
total and pull-down gels), whereas the C-terminal cyclin fold
and theC terminus (the 309–432 fragment) did not bind p27 or
Skp2N. Cyclin A with an N-terminal truncation to residue 173
(whichwas previously used for crystal structure analysis) bound
to p27 to a similar extent as full-length cyclin A but barely
detectably to Skp2N. This result is in agreement with the deter-
mination of HP to be the p27 binding site by crystal structure
studies and indicates that a distinct site upstreamof residue 173
provides major binding affinity for Skp2N. Consistent with this
notion, cyclin A fragment 1–208 can bind to Skp2N but not
p27. Identification of the cyclin A N terminus as the major
binding site for Skp2N may provide a structural basis for the
cyclin specificity of the Skp2-cyclin A interaction because,
unlike the cyclin-box sequences, cyclin A N-terminal
sequences are not conserved in other cyclins. Indeed, as shown
in Fig. 4, D and E, Skp2N did not
interact with cyclin E-Cdk2 or
cyclin D1-Cdk4, whereas p27
showed stable binding to these
cyclins.
Skp2-Cyclin A Interaction and
p27-Cyclin A Interaction Can Be
Blocked by Distinct Peptides—Mu-
tation analysis to map the required
interaction sequences leaves open
the possibility that certain muta-
tions may alter binding indirectly
through influencing general protein
conformation rather than directly
serving as the interacting site. An
important aspect of RXL-HP inter-
action is that it can be blocked by a
short RXL peptide (17). If Skp2-cy-
clin A-Cdk2 interaction and p27-
cyclinA-Cdk2 interaction aremedi-
ated by different sequences on both
sides of the interaction, as shown
above, it can be predicted that the
RXL peptide should not block Skp2-
cyclin A interaction. We also deter-
mined whether an 18-residue pep-
tide replica derived from Skp2
sequences between 40 and 60
(called the 4060 peptide) could
block Skp2-cyclin A interaction but
not p27-cyclin A interaction. Our
results show that the 4060 peptide
can block interaction between
Skp2Nand cyclinAbut not between
p27 and cyclin A (Fig. 5A, lanes 9
and 10 and lanes 4 and 5). Muta-
tions of the four conserved residues
to alanine (the 4060AAAA peptide)
abolished the blocking activity of the 4060 peptide (lanes 11 and
12). The RXL peptide has the opposite effects (blocking p27-
cyclin A interaction but not Skp2N-cyclin A interaction) (lanes
2 and 3 and lanes 6 and 7). Peptide concentrations required for
their respective blocking activities were similar for RXL and
4060 peptides. The 4060 peptide, but not the RXL peptide, also
blocked binding between full-length GST-Skp2 and cyclin
A-Cdk2 (Fig. 5B). These results provide strong evidence that
the Skp2 40–60 sequence contains a novel cyclin A interacting
domain and Skp2-cyclin A interaction is distinct from the
RXL-HP interaction.
Skp2 Competes with p27/p21, but Not E2F1, for Binding to
Cyclin A—The original findings that transformed cells contained
exclusively cyclin A-Cdk2-Skp2 complexes, whereas untrans-
formed cells contained exclusively cyclin A-Cdk2-p21 complexes
raised the possibility that these two complexes might bemutually
exclusive (8, 9). It was further demonstrated that transfected p21
could reduce cyclin A-Cdk2-Skp2 interaction (14). Our determi-
nation that Skp2-cyclin A-Cdk2 interaction is distinct from p27-
cyclin A-Cdk2 interaction prompted us to revisit this topic. We
FIGURE 3. Comparison of binding efficiencies of Skp2-cyclin A and p27-cyclin A. A, Immunoprecipitation-
Western assay of transfected 293T cell extracts as indicated. B, GST pull-down assays with GST, GST-p27,
GST-Skp2, or GST-Skp2N and 293T cell extracts transfected with Myc-cyclin A and Cdk2. C, GST pull-down
assays as in B except two GST-Skp2N mutants were included. D, GST pull-down assay with the indicated
GST-fusion proteins and baculovirally produced and purified GST-cyclin A-Cdk2 complex after GST cleavage.
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first determined whether the competition between Skp2 and p21
for cyclin A-Cdk2 binding could be observed in vivowith endoge-
nousproteinsunderphysiological conditions. For thispurpose,we
treated U2OS cells with actinomycin D to activate p53, which led
to a significant increase in p21 protein levels. As shown in Fig. 6A,
a significant increase in p21 levels after actinomycin D treatment
in the assay conditions did not change protein levels of Skp2 and
cyclinA (lanes 1 and2) but decreased Skp2-cyclinA interaction to
background levels (lanes 4 and 5) with increased binding of cyclin
A to p21 (lanes 6 and 7), documenting that competition between
p21 and Skp2 for cyclin A binding is a physiological process.
We next determined whether Skp2 competes with other RXL
proteins for cyclin A binding. Using GST pull-down assays, we
compared p21, p27, and another well established RXL protein
E2F1 (22). E2F1differs fromp21/p27 as a cyclinA-bindingprotein
in that it does not inhibit cyclin
A-Cdk2kinaseactivity and ismainly a
phosphorylation substrate. As shown
in Fig. 6B, by including progressively
higher concentrations of Skp2N in a
binding reaction with fixed amounts
of GST-p21 and cyclin A-Cdk2, p21
binding to cyclin A was progressively
diminished, confirming the previous
finding (14). In parallel experiments
we show that Skp2N also competed
with GST-p27 for binding to cyclin
A-Cdk2 (Fig. 6C). Interestingly,
Skp2N did not affect E2F1-cyclin A
binding, whereas p27 efficiently
blocked it as expected (Fig. 6D). Thus,
Skp2 binding to cyclin A does not
block interaction of cyclin A with all
RXL proteins, which is consistent
with the fact that, unlike p27, Skp2
does not use the RXL-HPmechanism
to interact with cyclin A. Finally, we
show in Fig. 6E that Skp2N did not
compete with p27 for binding to
cyclin E-Cdk2, which is consistent
with the finding inFig. 4D that Skp2N
did not bind cyclin E-Cdk2. How
Skp2 competes with p21/p27 for
cyclin A binding and how Skp2 dis-
criminates between p21/p27 and
E2F1 (and potentially other cyclin A
bindingproteins) for competitionwill
requiremoredetailed structural stud-
ies. Nevertheless, these binding char-
acteristics apparently provide a
molecular explanation for the regula-
tory effects of Skp2 on cyclin A-Cdk2
kinase activity described below.
Skp2-Cyclin A Interaction Directly
Protects Cyclin A-Cdk2 from Inhibi-
tion by p27—Effects of Skp2-cyclin
A interaction on cyclin A-Cdk2
kinase activity has remained
unclear and controversial. In the original report, Beach and
co-workers (9) showed that Skp2-cyclin A-Cdk2 interaction
did not inhibit nor stimulate cyclin A-Cdk2 kinase activity.
To the contrary, Poon and co-workers (14) provided evi-
dence that Skp2 could inhibit cyclin A-Cdk2 kinase activity.
We reasoned that a better way to determine the effects of
Skp2 on cyclin A-Cdk2 kinase activity is to compare Skp2
with a well established CKI-like p27 and relate the amounts
and ratios of relevant proteins used in vitro to the respective
amounts and ratios of the same proteins in cells. We also
used purified proteins in soluble reactions to measure kinase
activity under equilibrium conditions to avoid complications
associated with immunoprecipitation of the kinases. These
types of biochemical studies have been previously performed
for p21, p27, and related CKIs (23).
FIGURE 4. Skp2 does not interact with Cdk2 alone and interacts with N terminus of cyclin A. A, GST
pull-down assay with indicated GST fusion proteins and 293T cell extracts transfected with indicated expres-
sion vectors. B, a schematic drawing of cyclin A domain structure and various mutants used in C. C, GST
pull-down assay as in A with indicated GST fusion proteins and cell extracts transfected with various cyclin A
mutants. WT, wild type. D and E, GST pull-down assays as in A except with cyclin E (Cyc E)-Cdk2 or cyclin
D1-Cdk4-transfected cell extracts. The asterisk indicates background bands.
FIGURE 5. Skp2-cyclin A interaction and p27-cyclin A interaction are blocked by distinct peptides. A, GST
pull-downassaywith indicatedGST fusionproteins andMyc-cyclinA-Cdk2-transfected293T cell extracts in the
absence and presence of various indicated peptides at indicated concentrations. B, same as in A, except
GST-Skp2 was used.
Direct Protection of Cyclin A by Skp2
AUGUST 18, 2006•VOLUME 281•NUMBER 33 JOURNAL OF BIOLOGICAL CHEMISTRY 24063
 at NYU School of M
edicine Library on January 5, 2007 
www.jbc.org
Downloaded from
 
For kinase reactions we used insect cell-produced and -puri-
fied GST-cyclin A-Cdk2 at a concentration of $3 nM, which
wasthelowestconcentrationthatyieldedreadilydetectiblephos-
phorylation ofGST-Rb-C in our assay. Purified p27, GST-Skp2,
and Skp2N were titrated into the kinase reaction over a wide
range of concentrations as shown in Fig. 7, A–C. Phosphoryla-
tion of Rb-C was measured and plotted, and the IC50 of these
various proteins were determined by non-linear least squares
analysis (Fig. 7F). Results show that p27 inhibited cyclin
A-Cdk2 kinase activity with an IC50 of$2 nM. In the same assay
conditions, GST-Skp2 and Skp2N could also inhibit the kinase
activity although their IC50 values of $180 and $520 nM,
respectively, are significantly higher than that of p27. At this
high concentration Skp2N may also inhibit cyclin A-Cdk2
kinase by a substrate competition mechanism since Ser-76 of
Skp2 can be phosphorylated by cyclinA-Cdk2 (Fig. 2D). Results
from this series of experiments suggest that previous discrepant
results of Skp2 effects on cyclin A-Cdk2 kinase activity could be
due to different amounts of Skp2 used in the kinase assays.
We wished to determine whether the observed inhibitory
effects of Skp2 has physiological relevance by measuring the
amounts and ratios of relevant proteins in cells and comparing
them with ratios used in kinase
assays. Skp2 forms abundant com-
plexes with cyclin A in tumor cells
due to its frequent overexpression.
We used HeLa cells, which contain
higher levels of Skp2 comparedwith
a number of commonly used cell
lines (data not shown), to determine
whether Skp2 to cyclinA ratios, that
resulted in kinase inhibition in
kinase assays, could be reached in
cells. Because Skp2, p27, and cy-
clin A levels oscillate in the cell
cycle, we determined their levels
in synchronized cell populations
obtained at various time points after
release from mitotic arrest by
nocodazole as shown in Fig. 7G. We
quantified the quantities of p27,
Skp2, and cyclin A in HeLa cells at
various cell cycle stages by compar-
ing them with known amounts of
purified Skp2N, p27, and cyclin A in
the sameWestern blots (see “Exper-
imental Procedures”). We then
determined the molar ratios of p27/
cyclin A and Skp2/cyclin A at repre-
sentative time points in the cell
cycle. As presented in Fig. 7G, the
p27/cyclin A molar ratio is $1.0 at
14 h, when cyclin A is starting to
accumulate, and $0.01 at 19 h,
when cyclin A has reached signifi-
cant levels, whereas p27 levels
decreased. Because the IC50 of p27
is$2 nM in the kinase reaction con-
taining 3 nM cyclin A, these molar ratios suggest that p27 could
function as an effective CKI at the 14-h time point but not at
19-h time points. When the same analysis was applied to Skp2,
it was revealed that the highest Skp2-cyclin Amolar ratio found
at 3 h is about$5,which iswell below themolar ratio at the IC50
of Skp2 ($180 nMSkp2 over 3 nM cyclinA-Cdk2). Although it is
formally possible that certain factors could affect or modify the
activity of Skp2 in vivo, the large gap between Skp2-cyclin A
molar ratios in vivo and that required to reach IC50 in vitro
suggests that Skp2 is unlikely to function as an inhibitor of
cyclin A-Cdk2 kinase activity.
Because Skp2 competes with p27 for binding to cyclin A and
Skp2 IC50 is about 100-fold higher than the p27 IC50, we rea-
soned that at concentrations well below its IC50, Skp2 might be
able to protect cyclin A-Cdk2 from inhibition by p27. To test
this hypothesis we carried out the same cyclin A-Cdk2 kinase
assay to determine the inhibitory activity of p27 in the presence
of 80 nM Skp2N. The results in Fig. 7,D and E, show that inclu-
sion of Skp2N, but not Skp2N-AA45, increased the IC50 of p27
from$2 to$80 nM, revealing such a protective effect of Skp2.
Protein molar ratio analysis suggests that this protective effect
of Skp2 could be effective at the 14-h time point when cyclin A
FIGURE 6. Skp2 competes with p21/p27, but not E2F1, for binding to cyclin A. A, U2OS cells were treated
with 180 nM actinomycin D (Act D) for 20 h. Cell extracts were used for immunoprecipitation (IP)-Western
blotting as indicated. Cyc A, cyclin A. B, GST pull-down assay with GST-p21 and Myc-cyclin A-Cdk2-transfected
293T cell extracts. Increasing amounts of eluted and GST-cleaved Skp2N were added as indicated. C and D, GST
pull-down assay as in B except GST-p27 and GST-E2F1 were used as indicated. E, GST pull-down assay as in C,
except extract expressing Myc-cyclin E-Cdk2 was used.
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levels start to rise and Skp2 is present in about a 2-fold excess
over p27 (Fig. 7G).
The AAAA Mutation Compromises Skp2 Proliferation Stim-
ulatory Activity without Affecting Its Ability to Cause Degrada-
tion of Cellular p27 and p21—Skp2 exhibits proliferation-pro-
moting activities in various assays, which have been attributed
to Skp2-mediated p27 ubiquitylation and degradation. With a
better understanding of the Skp2-cyclin A interaction and the
ability to disrupt this interaction with point mutations that did
not affect the Skp2 ubiquitylating function, we next determined
the role of Skp2-cyclin A interaction in the proliferation-stim-
ulating activity of Skp2. Similar with the experiment shown in
Fig. 6A, we treatedU2OS cells with actinomycinD,which led to
activation of p53, stimulation of p21 expression, and G1 cell
cycle arrest, manifested by a $20% increase in G1 phase cells
(Fig. 8, A and D). We overexpressed Skp2 in U2OS cells to
determine whether Skp2 could counter the G1 cell cycle arrest
mediated by this actinomycin D-triggered checkpoint.
In untreated cells overexpression of Skp2 led to a significant
reduction of p27 levels (Fig. 8A, anti-p27 Western blot) and a
marked increase in cyclin A-associated kinase activity meas-
ured with anti-cyclin A immunoprecipitates (Fig. 8B). Overex-
pression of Skp2AAAA to similar levels as Skp2 reduced p27
levels and increased cyclin A-asso-
ciated kinase activity to similar
degrees, consistent with the finding
that Skp2AAAA was able to medi-
ate p27 ubiquitylation in vitro (Fig.
2B). Overexpression of Skp2 also led
to a slight ($4%) increase in S-phase
populations (Fig. 8D). Overexpres-
sion of Skp2AAAA, however, did
not have this effect.
Incells treatedwithactinomycinD,
activation of p53, as demonstrated by
increases in p53 protein levels, was
not affected by overexpression of
either Skp2 or Skp2AAAA (Fig. 8A).
On the other hand, overexpression of
Skp2 largely prevented the increase in
p21 levels (which is consistent with
previous findings that Skp2 can also
target p21 for ubiquitylation (5))
(Fig. 8A) and the decrease in cyclin
A-associated kinase activity after
actinomycin D treatment (Fig. 8B).
In comparison, overexpression of
Skp2AAAA was fully competent in
reducing p21 protein levels after
actinomycin D treatment but was
compromised in maintaining cyclin
A-associated kinase activity. This
defect inmaintaining cyclin A-asso-
ciated kinase activity correlated
with more cyclin A-p21 association
in cells expressing Skp2AAAA than
in cells expressing Skp2 after actino-
mycin D treatment (Fig. 8C), which
is consistent with results shown in Fig. 6A.
More importantly, Skp2AAAA exhibited a clear func-
tional defect in countering G1/S cell cycle arrest induced by
actinomycin D treatment. As shown in Fig. 8D, overexpres-
sion of Skp2 largely prevented G1/S cell cycle arrest after
actinomycin D treatment, as manifested by only a 5%
increase in G1 cell population as compared with a 20%
increase in G1 cell populations in uninfected and GFP-in-
fected cells. In contrast, actinomycin D treatment still led to
a 15% increase in G1 cell populations in the presence of over-
expression of Skp2AAAA.
To determine and compare the ability of Skp2 and Skp2AAAA
to counter p53/p21-mediated cell cycle arrest in another context,
we treated cells with another commonly used DNA-damaging
agent etoposide. Consistent with results obtained with actinomy-
cinDtreatment, treatmentofU2OScellswith etoposide increased
protein levels of cellular p53 and p21, and overexpression of Skp2
and Skp2AAAA similarly prevented the increases in p21 levels
after etoposide treatment (data not shown). Treatment of GFP-
infected U2OS cells with etoposide led to accumulation of cells in
S phase by fluorescence-activated cell sorter analysis (data not
shown)and inhibitionofactiveDNAsynthesis asdemonstratedby
a decrease in the fractions of BrdUrd-positive cells from80 to 29%
FIGURE 7. Regulation of cyclin A-Cdk2 kinase activity by Skp2. A–E, kinase reaction using purified cyclin
A-Cdk2 at$3 nM. Increasing concentrations of purified p27, GST-Skp2, Skp2N, and Skp2N-AA45 were included
in the kinase reaction as indicated. F, phosphorylation of Rb-C was quantified and plotted to determine the Ki
of various proteins. G, HeLa cells were arrested in mitotic phase with nocodazole treatment and released into
fresh media at time 0. Fractions of cells were harvested at the indicated time points, and cellular protein levels
of p27, Skp2, and cyclin A were determined with Western blotting. Determination of various molar ratios was
described under “Experimental Procedures.”
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after a 24-h treatment (Fig. 8E). These effects suggested that,
unlike actinomycin D, etoposide treatment of U2OS cells largely
led to intra-S-phase arrest. In this cellular context, overexpression
of Skp2 led to a net increase of 17% in the fraction of BrdUrd-
positive cells over the 29% BrdUrd labeling index of etoposide-
treated GFP-infected cells. In contrast, overexpression of
Skp2AAAAincreased theBrdUrd labeling indexover that ofGFP-
infected cells by only 4% (Fig. 8E).We conclude from these results
that Skp2-cyclinA interaction has a significant role in Skp2 prolif-
eration-stimulating activity in countering cell cycle arrest by p53/
p21-mediated cell cycle checkpoint without affecting its ability to
cause degradation of cellular p27 and p21.
FIGURE 8. The AAAA mutation does not affect Skp2-medaited degradation of p27 and p21 but significantly compromises Skp2 ability to counter a
p53-p21mediatedG1 cell cycle arrest.A, U2OS cellswere infectedwith various lentiviruses as indicated and treatedwith actinomycinD (Act D) for 20 h. Total
cell extracts were analyzed by Western blotting. Cyc A, cyclin A. B, the same cell extracts as in A were used for immunoprecipitation (IP) with an anti-cyclin A
antibody. The immunoprecipitates were used for a kinase reaction with GST-Rb-C as substrate. C, the same cell extracts were used for immunoprecipitation
with an anti-cyclin A antibody followed by Western blotting as indicated. D, the same cells were stained with propidium iodide, and their DNA profiles were
determined by flow cytometry. Results presented here are representatives of three separate experiments. E, U2OS cells infected with GFP, FLAG-Skp2, and
FLAG-Skp2AAAA as indicated were treated with etoposide (Eto) for 24 h. Cells were labeled with BrdUrd for the last 2 h before fixation for BrdUrd indirect
immunofluorescence staining. Nearly 200 cells were scored for BrdUrd staining. Results from three experiments were averaged with error bars as shown.
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DISCUSSION
Skp2-Cyclin A Interaction Reveals a Novel Way to Physically
Interact with Cyclin A—Cyclin-Cdk as a core kinase complex
interacts with other proteins for regulation and substrate
recruitment. Interaction between theHP of a cyclin and anRXL
motif of an interacting protein represents a paradigm of this
relationship. Skp2 contains a potential RXL motif (the KXL376
sequence), and mutation of KXL376 to AAA376 abolished its
interaction with cyclin A, suggesting that Skp2 belongs to the
RXL protein family (13). Interestingly, the AAA376 mutation
also abolished Skp2-Skp1 binding (13), suggesting that this
mutation might have multiple effects. Subsequent x-ray crystal
structure studies revealed that Skp2 (with N-terminal trunca-
tion of 100 residues) has a rigid structure shaped like a sickle
(15). Skp2 F-box sequence and Skp1 together form the handle,
whereas the KXL376 sequence is buried inside the curved blade.
Based on this structural feature, it is likely that the effects
induced by the AAA376 mutation could be due to more general
protein conformational changes.
Results from our current study identify a non-RXL cyclin A
binding domain in the Skp2 N terminus. Skp2 sequences
between amino acid residues 40–60 are required for cyclin A
binding and are highly evolutionally conserved, and point
mutations of the four most conserved residues are sufficient to
disrupt Skp2-cyclin A interaction. Because the Skp2 N-termi-
nal sequences were not included in the solved Skp2 structure, it
is not known whether this 40–60 sequence is surface-exposed
for protein-protein interaction. Nevertheless, our findings that
the 4060 peptide, but not the RXL peptide, can block Skp2-
cyclin A interaction, and vice versa, that the RXL peptide, but
not the 4060 peptide, can block p27-cyclin A-Cdk2 interaction
provide strong evidence for the presence of a non-RXL cyclin
A-interacting sequence between Skp2 residues 40 and 60.
On the cyclin A side, Skp2-cyclin A interaction also differs
from the RXL-HP interaction. When Skp2 and p27 were stud-
ied together, ourmapping results show that the binding sites on
cyclin A for these two proteins are distinct, with the Skp2 bind-
ing site located N-terminal to the HP site on the cyclin A N
terminus. At the amino acid sequence level, mapping of the
Skp2 interaction site to the N terminus provides a structural
explanation for the cyclin specificity of the Skp2-cyclin A inter-
action since theN-terminal sequences of cyclinA are not highly
conserved in other cyclins. This finding suggests an interesting
possibility that the N termini of various cyclins could be
exploited to subject them to specific regulation. In this respect,
it will be interesting to understand with further studies the rea-
sons for Skp2 to specifically target cyclinA. A cluemay lie in the
fact that cyclin A is unique in the cyclin family in that it plays
important roles in both G1/S and G2/M phases of the cell cycle.
The RXL-HP interaction has been believed to be a general
mechanism mediating relationships between cyclins and non-
Cdk proteins. Determination that Skp2-cyclin A interaction
represents a novel physical relationship between cyclin A and
non-Cdk proteins broadens our view of how cyclins and non-
Cdk proteins could interact, which should lead to new knowl-
edge of how cyclins and non-Cdk proteins communicate and
regulate each other.
Significance of Skp2-Cyclin A Interaction in Skp2-mediated
p27 Ubiquitylation—In addition to phosphorylating p27 at
Thr-187, cyclin A-Cdk2 complex (or cyclin E-Cdk2 complex) is
also required to form trimeric complexes with p27 for its ubiq-
uitylation by Skp2 (24). One clue to the nature of this require-
ment stemmed from the identification of Cks1 as an essential
cofactor in p27 ubiquitylation by Skp2 (25, 26). Because Cks1 is
a high affinity Cdk2-binding protein (27), interactions between
Cks1 and Cdk2 may facilitate the recruitment of the trimeric
cyclin A-Cdk2-p27 complex to Skp2. Structure and mutagene-
sis studies of Cks1 suggested that Cks1 is a three-faceted pro-
tein, and it uses its three binding interfaces to separately inter-
act with Skp2, Cdk2, and phosphorylated p27 to organize these
proteins into a super-complex (28). In this model phosphoryl-
ated p27 simultaneously interacts with cyclin A-Cdk2 (via the
RXL-HP interface), Cks1 (via phosphorylated Thr-187 and the
Cks1 anion-binding site), and Skp2. Interaction between
Skp2 and cyclin A is mediated through Cdk2-Cks1, with
Cks1 directly bound near the C terminus of Skp2 (29). The
Skp2 N terminus is not involved, and no clear distinctions
exist between the roles of cyclin A and cyclin E in this
super-complex.
X-ray crystal structure studies have provided direct and
more detailed evidence for the formation of a cyclin A-Cdk2-
Cks1-Skp2-p27 super-complex as proposed above. An N-
terminal-truncated Skp2 (Skp2#N) is able to form a
SCFSkp2#N!Roc1 complex through the F-box (15, 20) and
Skp2#N-Cks1-p27 complex through the C-terminal blade
(30). Superimposing the available cyclin A-Cdk2, Cdk2-Cks1,
Skp1-Skp2#N-Cks1-p27, and Skp2#N-Skp1-Cul1-Roc1 struc-
tures demonstrated that a super-complex of Skp1-Skp2#N-
Cks1-Cdk2-cyclin A-p27 could indeed form on Skp2 (30).
Skp2#N also coeluted with Skp1, Cul1, Roc1, Cks1, p27, Cdk2,
and cyclin A from size-exclusion chromatographic columns,
providing experimental evidence for such an eight-subunit
complex in the absence of the Skp2 N terminus (30).
Interestingly, Koff and co-workers (31) recently reported
that bacterially produced Skp2#N (which was used for x-ray
crystal structure studies) was unable to bind cyclin A and ubiq-
uitylate p27. This result suggested that the eight-subunit com-
plex formedwith Skp2#Nwould be functionally inactive in p27
ubiquitylation. A conceivable mechanism for the requirement
for the N-terminal-bound cyclin A is that, whereas cyclin A can
be tethered onto the Skp2 C terminus via Cks1-Cdk2-cyclin A
interaction, an additional interaction between cyclin A and the
Skp2 N terminus is needed to strengthen and/or reshape this
super-complex for it to be active. Our finding that the Skp2 N
terminus and p27 compete for binding to cyclin A-Cdk2makes
this scenario unlikely since when cyclin A-Cdk2 is bound to the
Skp2 N terminus, it will not be able to bind p27 to form the
trimeric complex. Our results that the Skp2AAAAmutant lost
interaction with cyclin A but was able to ubiquitylate p27 pro-
vide experimental evidence that an N-terminal-bound cyclin A
is not required for Skp2 to mediate p27 ubiquitylation. Impor-
tantly, Skp2#N was also able to mediate p27 ubiquitylation
when coexpressed in 293T cells with Skp1-Cul1-Roc1 (11).We
further found that baculovirus-produced and -purified
Skp2#N is fully competent in mediating p27 ubiquitylation;
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bacterially produced and purified Skp2#N also sustained
robust p27 ubiquitylation.7 Currently, we cannot explain the
reasons of the discrepancies between Koff and co-workers’
result and ours. Finally, like Skp2AAAA, Skp2#N was also
active in promoting degradation of p27 and p21 in cells (32).
Considered together, we are confident that cyclin A binding to
Skp2 N terminus is not required for p27 ubiquitylation.
Skp2-Cyclin A Interaction Represents a New Regulatory
Mechanism of Cyclin A-Cdk2 and a New Functional Mecha-
nism for Skp2 Proliferation-stimulating Activity—With respect
to regulation of cyclin/Cdk by a stably bound protein, the CKI
p27 is the best-understood example. In addition to the RXL-HP
interface, an N-terminal sequence (residues 85–90) of p27
inserts itself into the catalytic cleft of Cdk2 to block ATP
binding (18).With this mechanism, the relative concentrations
of p27 and cyclin-Cdk will determine the degree of kinase inhi-
bition. Skp2-mediated p27 ubiquitylation and degradation can
positively regulate cyclin-Cdk2 kinase activity by reducing p27
levels.
Our study of the Skp2-cyclin A interaction now reveals that
the inhibitory effect of p27 on cyclin A-Cdk2 can also be regu-
lated by Skp2 independent of p27 ubiquitylation and degrada-
tion. Skp2 competes with p27 for binding to cyclin A-Cdk2, but
Skp2 itself does not inhibit cyclin A-Cdk2 at physiologically
relevant concentrations. This property of Skp2 forms the
mechanistic basis for Skp2 to exert a positive effect on cyclin
A-Cdk2 whenever p27 is present. Our determination that the
presence of the Skp2N terminus at 80 nM in the kinase reaction
shifted the IC50 of p27 rightward from 2 to 80 nM indicates that
this protective effect of Skp2 N terminus is effective when the
molar ratio of Skp2 over p27 is about 1 or larger. We further
determined that the molar ratio of cellular Skp2 over p27 is
about 2 at 14 h after HeLa cells were released from mitotic
arrest when cyclinA protein levels are starting to rise. Although
other factors such as cellular localization or compartmentaliza-
tion can certainly affect the effective concentrations of Skp2
and p27 in vivo, we take our results to suggest that the protec-
tive effect of Skp2 could be physiologically relevant, at least
when Skp2 is overexpressed in tumor cells. Our findings, there-
fore, add a new mechanism of regulation of cyclin A-Cdk2
kinase activity in that the outcome of regulation of cyclin
A-Cdk2 kinase activity by p27 is determined not only by its
levels but also by the levels of Skp2. This new mechanism is
likely to be applicable to p27 familymember p21 since Skp2 and
p21 also compete for cyclin A binding. It is, however, important
to note that whether this protective effect of Skp2-cyclin A
interaction is an effective way to positively regulate cyclin A in
normal cells (where Skp2 levels are significantly lower) will
need to be determined with further studies, preferentially by
knocking-in the AAAA mutation.
By revealing the functional significance of Skp2-cyclin A
interaction, our study also adds a new functional mechanism
for Skp2 proliferation-stimulating activity. In assays that meas-
ure the ability of Skp2 to counter cell cycle arrest by p53/p21-
mediated cell cycle checkpoint, we found that point mutations
that disrupt Skp2-cyclin A interaction but not p27 ubiquityla-
tion and degradation significantly compromised the ability of
Skp2 to counter cell cycle arrest, revealing the importance of
Skp2-cyclin A interaction in Skp2 function in addition
to p27 ubiquitylation and degradation in the context of
overexpression.
The fact that Skp2 protein is often overexpressed and forms
abundant Skp2-cyclin A complexes in various cancer cells sug-
gests that Skp2 direct protective effects on cyclin Amay play an
important role in natural tumorigenesis as well. In this respect
it is of note thatwhereas the inverse correlation of Skp2 and p27
levels have been found in a large number of cancer samples,
cancer samples with high Skp2 but no reduction of p27 clearly
exist (for prostate cancer as an example, see Refs. 33–35). In
these cancer cells it is conceivable that certain steps for p27
ubiquitylation and/or degradation may have been disrupted to
render Skp2 p27 ubiquitylation activity ineffective, but Skp2
direct protective effects of cyclin A should remain effective and
could drive selection for Skp2 overexpression during tumori-
genesis. In mouse models, ectopic expression of Skp2 in pros-
tate epithelium induced a hyperplasia phenotype at 3–7
months of age (36), whereas p27 knock-outmice displayed sim-
ilar hyperplasia only when aged to 14 months (37). Further-
more, ectopic expression of Skp2 induced dysplasia and low
grade carcinoma in prostate epithelium (36), whereas such
abnormalities have not been observed in p27 knock-out mice.
New knowledge of the Skp2-cyclin A interaction should help
shed light on these intriguing observations and, in the mean-
time, help reveal new targets for inhibiting proliferation of
Skp2-overexpressing tumor cells.
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